Clearmind Medicine Inc., a foreign private issuer, has filed a Report on Form 6-K with the United States Securities and Exchange Commission for February 2024, confirming its compliance with the shareholders' equity requirement for continued listing on the Nasdaq Capital Market. The company had previously reported shareholders' equity below the $2.5 million threshold as of October 31, 2023. However, Clearmind Medicine has since increased its shareholders' equity to approximately $7 million, following the exercise of warrants from its March and September 2023 public offerings and a registered direct offering and private placement in January 2024. The company believes it has regained compliance with the Nasdaq's listing requirements and understands that Nasdaq will monitor its ongoing compliance, with potential delisting if non-compliance is found in the next interim report.

Clearmind Medicine Inc., a foreign private issuer, has filed a Report on Form 6-K with the United States Securities and Exchange Commission for February 2024, confirming its compliance with the shareholders' equity requirement for continued listing on the Nasdaq Capital Market. The company had previously reported shareholders' equity below the $2.5 million threshold as of October 31, 2023. However, Clearmind Medicine has since increased its shareholders' equity to approximately $7 million, following the exercise of warrants from its March and September 2023 public offerings and a registered direct offering and private placement in January 2024. The company believes it has regained compliance with the Nasdaq's listing requirements and understands that Nasdaq will monitor its ongoing compliance, with potential delisting if non-compliance is found in the next interim report.